Lidbree (Lidocaine)

Lidocaine works by blocking voltage‑gated sodium channels on nerve fibers within the uterine lining. This inhibition prevents the rapid influx of sodium ions needed for action potential generation, thereby halting nerve impulse transmission and producing a reversible loss of sensation in the treated area.

The specific dose and volume of Lidbree are determined by the prescribing clinician based on the procedure, patient characteristics, and clinical guidelines. Healthcare professionals calculate the appropriate amount to achieve effective local anesthesia while minimizing systemic exposure.

Safety data for intrauterine lidocaine during pregnancy or lactation are limited. Clinicians should evaluate the potential benefits against any possible risks, considering that lidocaine can cross the placental barrier. Use is generally reserved for situations where the therapeutic advantage outweighs potential concerns.

To request Lidbree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lidbree’s active ingredient, lidocaine, is a well‑established local anesthetic with a rapid onset and moderate duration of action. Compared with alternatives such as bupivacaine, lidocaine offers a shorter half‑life, which can be advantageous for brief procedures, while still delivering effective analgesia and a favorable safety profile when used correctly.

Lidbree should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. The product remains stable at room temperature, but exposure to extreme heat or humidity may compromise sterility and potency. Follow the label instructions for handling and discard any vial that appears compromised.

Lidbree is supplied as a sterile solution for intrauterine administration. A qualified healthcare professional injects the prescribed volume directly into the uterine cavity using a suitable catheter or applicator, typically immediately before the intended gynecologic procedure to achieve localized anesthesia.

The most serious risks include systemic toxicity leading to cardiac arrhythmias, seizures, or severe allergic reactions such as anaphylaxis. Prompt recognition of symptoms—such as dizziness, palpitations, or respiratory distress—and immediate medical intervention are essential to mitigate these rare but critical events.

Lidbree is contraindicated in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking medications that markedly increase lidocaine plasma levels. Clinical judgment should guide use in these populations.